Weekly Trademark Review May 19, 2015
This article was originally published in The Rose Sheet
You may also be interested in...
Novavax has granted Serum Institute rights to develop, manufacture and commercialize its COVID-19 vaccine candidate in a few regions. The agreement, which expands on an earlier association, gives Serum exclusive marketing rights in India till deal ends and non-exclusive rights for developing countries till pandemic lasts, with Novavax getting half of net revenue.
The market for heart failure diagnostics and devices is set to grow by 3.8% annually in the next three years, with emerging markets leading the growth, according to the new Meddevicetracker Dashboard.
Perrigo management provided colorful commentary on Perrigo’s latest endeavors to separate the company’s US generics business, following the recent sale of Perrigo’s Rosemont Pharmaceuticals subsidiary for an “attractive” multiple.